Cyclacel Pharmaceuticals - 53 Year Dividend History | CYCC
Historical dividend payout and yield for Cyclacel Pharmaceuticals (CYCC) since 1971. The current TTM dividend payout for Cyclacel Pharmaceuticals (CYCC) as of November 19, 2024 is $0.00. The current dividend yield for Cyclacel Pharmaceuticals as of November 19, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.001B |
$0.000B |
|
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
